Pharmacologic Options for the Treatment of Sarcopenia

Calcified Tissue International

Volumn 98, Issue 4, 2016, Pages 319-333

  Morley, John E ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Frailty; Low muscle mass; Muscle function; Muscle loss; Sarcopenia

Indexed keywords

ACTIVIN RECEPTOR 2; AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ANABOLIC AGENT; CAPROMORELIN; CYTOKINE; ESPINDOLOL; GHRELIN; GROWTH HORMONE; IBUTAMOREN; MACIMORELIN; MICRORNA; MYOKINE; MYOSTATIN; PERINDOPRIL; RAMATERCEPT; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; TERASEMTIV; TESTOSTERONE; UNCLASSIFIED DRUG;

GENETICS; HUMAN; META ANALYSIS (TOPIC); MITOCHONDRION; NONHUMAN; PARABIOSIS; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN SYNTHESIS; RESISTANCE TRAINING; REVIEW; SARCOPENIA; VASCULAR BIOLOGY; DRUG DEVELOPMENT;

DRUG DISCOVERY; HUMANS; SARCOPENIA;

EID: 84932185019     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-015-0022-5     Document Type: Review

References (162)

1. Rosenberg IH, Roubenoff R (1995) Stalking sarcopenia. Ann Intern Med 123:727–728
2. Clark BC, Manini TM (2008) Sarcopenia =/= dynapenia. J Gerontol A Biol Sci Med Sci 63:829–834
3. Barbat-Artigas S, Rolland Y, Vellas B, Aubertin-Leheudre M (2013) Muscle quantity is not synonymous with muscle quality. J Am Med Dir Assoc 14:852.e1-7. doi:10.1016/j.jamda.2013.06.003
4. Manini TM, Clark BC (2012) Dynapenia and aging: an update. J Gerontol A 67:28–40
5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing 39:412–423
6. Landi F, Cruz-Jentoft AJ, Liperoti R, Russo A, Giovannini S, Tosato M, Capoluongo E, Bernabei R, Onder G (2013) Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study. Age Ageing 42:203–209
7. Landi F, Liperoti R, Fusco D, Mastropaolo S, Quattrociocchi D, Proia A, Tosato M, Bernabei R, Onder G (2012) Sarcopenia and mortality among older nursing home residents. J Am Med Dir Assoc 13:121–126
8. Lee WJ, Liu LK, Peng LN, Lin MH, Chen LK, ILAS Research Group (2013) Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the I-Lan longitudinal aging study. J Am Med Dir Assoc 14:528.e1-7
9. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G et al (2011) Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc 12:249–256
10. Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, Cederholm T, Coats AJ, Cummings SR, Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop et al (2011) Sarcopenia with limited mobility: An international consensus. J Am Med Dir Assoc 12:403–409
11. Dam TT, Peters KW, Fragala M, Cawthon PM, Harris TB, McLean R, Shardell M, Alley DE, Kenny A, Ferrucci L, Guralnik J, Kiel DP, Kritchevsky S, Vassileva MT, Studenski S (2014) An evidence-based comparison of operational criteria for the presence of sarcopenia. J Gerontol A 69:584–590
12. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, Lee JS, Lee WJ, Lee Y, Ck Liang, Limpawattana P, Lin CS, Peng LN, Satake S, Suzuki T, Won CW, Wu CH, Wu SN, Zhang T, Zeng P, Akishita M, Arai H (2014) Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 15:95–101
13. Woo J, Leung J, Morley JE (2014) Defining sarcopenia in terms of incident adverse outcomes. J Am Med Dir. doi:10.1016/jamda.2014.11.013
14. ® with and without bone mineral density. Calcif Tissue Int 90:1–13
15. Malmstrom TK, Morley JE (2013) SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 14:531–532
16. Woo J, Leung J, Morley JE (2014) Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc 15:630–634
17. Cao L, Chen S, Zou C, Ding X, Gao L, Liao Z, Liu G, Malmstrom TK, Morley JE, Flaherty JH, An Y, Dong B (2014) A pilot study of the SARC-F scale on screening sarcopenia and physical disability in the Chinese older people. J Nutr Health Aging 18:277–283
18. Malmstrom TK, Simonsick EM, Ferrucci L, Miller DK, Morley JE (2015) SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarc Muscle. doi:10.1002/jcsm.12048
19. Argiles JM, Anker SD, Evans WJ, Morley JE, Fearon KC, Strasser F, Muscaritoli M, Baracos VE (2010) Consensus on cachexia definitions. J Am Med Dir Assoc 11:229–230
20. Purves-Smith FM, Sgarioto N, Hepple RT (2014) Fiber typing in aging muscle. Exerc Sport Sci Rev 42:45–52
21. Hepple RT (2003) Sarcopenia: a critical perspective. Sci Aging Knowl Environ 45:31
22. Drey M, Grosch C, Neuwirth C, Bauer JM, Sieber CC (2013) The motor unit number index (MUNIX) in sarcopenic patients. Exp Gerontol 48:381–384
23. Hettwer S, Dahinden P, Kucsera S, Farina C, Ahmed S, Fariello R et al (2013) Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients. Exp Gerontol 48:69–75
24. Drey M, Krieger B, Sieber CC, Bauer JM, Hettwer S, Bertsch T, DISARCO Group (2014) Motoneuron loss is associated with sarcopenia. J Am Med Dir Assoc 15:435–439
25. McNeil CJ, Doherty TJ, Stashuk DW, Rice CL (2005) Motor unit number estimates in the tibialis anterior muscle of young, old, and very old men. Muscle Nerve 31:461–467
26. Guillet C, Auguste P, Mayo W, Kreher P, Gascan H (1999) Ciliary neurotrophic factor is a regulator of muscular strength in aging. J Neurosci 19:1257–1262
27. Arking DE, Fallin DM, Fried LP, Li T, Beamer BA, Xue QL, Chakravarti A, Walston J (2006) Variation in the ciliary neurotrophic factor gene and muscle strength in older Caucasian women. J Am Geriatr Soc 54:823–826
28. Demontis F, Piccirillo R, Goldberg AL, Perrimon N (2013) The influence of skeletal muscle on systemic aging and lifespan. Aging Cell 12:943–949
29. Iizuka K, Machida T, Hirafuji M (2014) Skeletal muscle is an endocrine organ. J Pharmacol Sci 125:125–131
30. Yoon JH, Kim J, Song P, Lee TG, Suh PG, Ryu SH (2012) Secretomics for skeletal muscle cells: a discovery of novel regulators? Adv Biol Regul 52:340–350
31. Pal M, Febbraio MA, Whitham M (2014) From cytokine to myokine: The emerging role of interleukin-6 in metabolic regulation. Immunol Cell Biol 92:331–339
32. Pistilli EE, Quinn LS (2013) From anabolic to oxidative: reconsidering the roles of Il-15 and IL-15Rα in skeletal muscle. Exerc Sport Sci Rev 41:100–106
33. Morley JE, von Haehling S, Anker SD, Vellas B (2014) From sarcopenia to frailty: a road less travelled. J Cachexia Sarcopenia Muscle 5:5–8
34. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J et al (2013) Frailty consensus: a call to action. J Am Med Dir Assoc 14:392–397
35. Garatachea N, Lucia A (2013) Genes and the ageing muscle: a review on genetic association studies. Age 35:207–233
36. Stewart CEH, Rittweger J (2006) Adaptive processes in skeletal muscle: molecular regulators and genetic influences. J Musculoskelet Neuronal Interact 6:783–786
37. Seto JT, Quinlan KG, Lek M, Zheng XF, Garton F, MacArthur DG et al (2013) ACTN3 genotype influences muscle performance through the regulation of calcineurin signaling. J Clin Invest 123:4255–4263
38. Seto JT, Chan S, Turner N, MacArthur DG, Raftery JM, Berman YD et al (2011) The effect of α-actinin-3 deficiency on muscle aging. Exp Gerontol 46:292–302
39. Dennis RA, Zhu H, Kortebein PM, Bush HM, Harvey JF, Sullivan DH, Peterson CA (2009) Muscle expression of genes associated with inflammation, growth, and remodeling is strongly correlated in older adults with resistance training outcomes. Physiol Genomics 38:169–175
40. Windelinckx A, De Mars G, Huygens W, Peeters MW, Vincent B, Wijmenga C, Lambrechts D et al (2011) Comprehensive fine mapping of chr12q12-14 and follow-up replication identify activin receptor 1B (ACVR1B) as a muscle strength gene. Eur J Hum Genet 19:208–215
41. Conte M, Vasuri F, Trisolino G, Bellavista E, Santoro A, Degiovanni A et al (2013) Increased Plin2 expression in human skeletal muscle is associated with sarcopenia and muscle weakness. PLoS ONE 8(8):e73709
42. Rolland Y, Lauwers-Cances V, Crostini C, Abellan van Kan G, Janssen I, Morley JE, Vellas B (2009) Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women. EPIDOS Study 89:1895–1900
43. Baumgartner RN, Wayne SJ, Waters DL, Janssen I, Gallagher D, Morley JE (2004) Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res 12:1995–2004
44. Amold A-S, Egger A, Handschin C (2011) PGC-1α and myokines in the aging muscle—a mini-review. Gerontology 57:37–43
45. Ling C, Poulsen P, Carlsson E, Ridderstrale M, Almgren P, Wojtaszewski J, Beck-Nielsen H, Groop L, Vaag A (2004) Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J Clin Invest 114:1518–1526
46. Sandri M, Lin J, Handschin C, Yang W, Zp Arany, Lecker SH, Goldberg AL, Spiegelman BM (2006) PGC-1α protects skeletal muscle from atrophy by suppressing fox03 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA 103:16260–16265
47. Hepple RT (2014) Mitochondrial involvement and impact in aging skeletal muscle. Front Aging Neurosci 6:211. doi:10.3389/fnagi.2014.00211
48. Marzetti E, Calvani R, Cesari M, Buford TW, Lorenzi M, Behnke BJ, Leeuwenburgh C (2013) Mitochondrial dysfunction and sarcopenia of aging: From signaling pathways to clinical trials. Int J Biochem Cell Biol 45:2288–2301
49. Coen PM, Jubrias SA, Distefano G, Amati F, Mackey DC, Glynn NW et al (2013) Skeletal muscle mitochondrial energetics are associated with maximal aerobic capacity and walking speed in older adults. J Gerontol A 68:447–455
50. 2+ homeostasis, autophagy, and lifespan? Free Radic Res 48:1109–1114
51. Wu CY, Chen YF, Wang CH, Kao CH, Zhuang HW, Chen CC, Chen LK et al (2012) A persistent level of Cisd2 extends healthy lifespan and delays aging in mice. Hum Mol Genet 21:3956–3968
52. Lawrenson L, Poole JG, Kim J, Brown C, Patel P, Richardson RS (2003) Vascular and metabolic response to isolated small muscle mass exercise: effect of age. Am J Physiol Heart Circ Physiol 285:H1023–H1031. doi:10.1152/ajpheart.00135.2003
53. Donato AJ, Uberoi A, Wray DW, Nishiyama S, Lawrenson L, Richardson RS (2006) Differential effects of aging on limb blood flow in humans. Am J Physiol Heart Circ Physiol 290:H272–H278
54. Seals DR, Jablonski KL, Donato AJ (2011) Aging and vascular endothelial function in humans. Clin Sci 120:357–375
55. Behnke BJ, Delp MD, Dougherty PJ, Musch TI, Poole DC (2005) Effects of aging on microvascular oxygen pressures in rat skeletal muscle. Respir Physiol Neurobiol 146:259–268
56. Cohen S, Nathan JA, Goldberg AL (2015) Muscle wasting in disease: molecular mechanisms and promising therapies. Nature 14:58–74
57. Cohen S, Brault JJ, Gygi SP, Glass DJ, Valenzuela DM, Geratner C, Latres E, Goldberg AL (2009) During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 185:1083–1095
58. Cohen S, Zhai B, Gygi SP, Goldberg AL (2012) Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J Cell Biol 198:575–589
59. Verdijk LB, Koopmans R, Schaart G, Meijer K, Savelberg HHCM, van Loon LJC (2007) Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. Am J Physiol Endocrinol Metab 292:E151–E157
60. McGregoe RA, Poppitt SD, Cameron-Smith D (2014) Role of microRNAs in the age-related changes in skeletal muscle and diet or exercise interventions to promote healthy aging in humans. Ageing Res Rev 17:25–33
61. Rivas DA, Lessard SJ, Rice NP, Lustgarten MS, So K, Goodyear LJ, Parnell LD, Fielding RA (2014) Diminished skeletal muscle microRNA expression with aging is associated with attenuated muscle plasticity and inhibition of IGF-1 signaling. FASEB J 28:4133–4147
62. Barbierato M, Zusso M, Skaper SD, Giusti P (2015) MicroRNAs: emerging role in the endogenous mu opioid system. CNS Neurol Disord Drug Targets 14:239–250
63. Alieva AKH, Filatova EV, Karabonov AV, Illarioshkin SN, Limborska SA, Shadrina MI, Slominsky PA (2015) miRNA expression is highly sensitive to a drug therapy in Parkinson’s disease. Parkinsonism Relat Disord 21:72–74
64. Kern H, Barberi L, Löfler S, Sbardella S, Burggraf S, Fruhmann H et al (2014) Electrical stimulation counteracts muscle decline in seniors. Front Aging Neurosci. doi:10.3389/fnagi.2014.00189
65. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA (2005) Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 433(7027):760–764
66. Sinha M, Jang YC, Oh J, Khong D, Wu EY, Manohar R, Miller C et al (2014) Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 344(6184):649–652
67. Sinha I, Sinha-Hikim AP, Wagers AJ, Sinha-Hikim I (2014) Testosterone is essential for skeletal muscle growth in aged mice in a heterochronic parabiosis model. Cell Tissue Res 357(3):815–821
68. Fuster G, Busquets S, Almendro V, Lopez-Soriano FJ, Argiles JM (2007) Antiproteolytic effects of plasma from hibernating bears: a new approach for muscle wasting therapy? Clin Nutr 26:658–661
69. Bodine SC (2013) Hibernation: The search for treatments to prevent disuse-induced skeletal muscle atrophy. Exper Neurol 248:129–135
70. Andres-Mateos E, Brinkmeier H, Burks TN, Mejias R, Files DC, Steinberger M, Soleimani A et al (2013) Activation of serum/glucocorticoid-induced kinase 1 (SGK1) is important to maintain skeletal muscle homeostasis and prevent atrophy. EMBO Mol Med 5:80–91
71. Valenzuela T (2012) Efficacy of progressive resistance training interventions in older adults in nursing homes: a systematic review. J Am Med Dir Assoc 13:418–428
72. Cadone Cadore EL, Izquierdo M (2013) New strategies for the concurrent strength-, power-, and endurance-training prescription in elderly individuals. J Am Med Dir Assoc 14:623–624
73. Singh NA, Quine S, Clemson LM, Williams EJ, Williamson DA, Stavrinos TM et al (2012) Effects of high-intensity progressive resistance training and targeted multidisciplinary treatment of frailty on mortality and nursing home admissions after hip fracture: a randomized controlled trial. J Am Med Dir Assoc 13:24–30
74. Pahor M, Guralnik JM, Ambrosius WT, Blair S, Bonds DE, Church TS et al (2014) Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA 311(23):2387–2396
75. Yamada M, Arai H, Sonoda T, Aoyama T (2012) Community-based exercise program is cost-effective by preventing care and disability in Japanese frail older adults. J Am Med Dir Assoc 13:507–511
76. Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE et al (2013) Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group. J Am Med Dir Assoc 14:542–559
77. Malafarina V, Uriz-Otano F, Iniesta R, Gil-Guerrero L (2013) Effectiveness of nutritional supplementation on muscle mass in treatment of sarcopenia in old age: a systematic review. J Am Med Dir Assoc 14:10–17
78. Boirie Y (2013) Fighting sarcopenia in older frail subjects: protein fuel for strength, exercise for mass. J Am Med Dir Assoc 14:140–143
79. Tieland M, van de Rest O, Dirks ML, van der Zwaluw N, Mensink M, van Loon LJ et al (2012) Protein supplementation improves physical performance in frail elderly people: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc 13:720–726
80. Cermak NM, de Groot LC, van Loon LJ (2013) Perspective: Protein supplementation during prolonged resistance type exercise training augments skeletal muscle mass and strength gains. J Am Med Dir Assoc 14:71–72
81. Gryson C, Ratel S, Rance M, Penando S, Bonhomme C, Le Ruyet P, Duclos M, Boirie Y, Walrand S (2014) Four-month course of soluble mil proteins interacts with exercise to improve muscle strength and delay fatigue in elderly participants. J Am Med Dir Assoc 15:958.e1-9
82. Ferrando AA, Paddon-Jones D, Hays NP, Kortebein P, Ronsen O, Williams RH, McComb A, Symons TB, Wolfe RR, Evans W (2010) EAA supplementation to increase nitrogen intake improves muscle function during bed rest in the elderly. Clin Nutr 29:18–23
83. Bauer JM, Verlaan S, Bautmans I, Brandt K, Donini LM, Maggio M, et al. (2015) Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults. The PROVIDE study: a randomized, double-blind, placebo-controlled trial. J Am Med Dir (in press)
84. Morley JE, Argiles JM, Evans WJ, Bhasin S, Cella D, Deutz NE et al (2010) Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc 11:391–396
85. Van Wetering C, Hoogendoorn M, Broekhuizen R, Geraerts-Keeris GJ, de Munck DR, Rutten-van Molken MP et al (2010) Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc 11:179–187
86. Tieland M, Dirks ML, van der Zwaluw N, Verdijk LB, van de Rest O, de Groot LC, van Loon LJ (2012) Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc 13:713–719
87. Beaudart C, Buckinx F, Rabenda V, Gillain S, Cavalier E, Slomian J et al (2014) The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 99:4336–4345
88. Murad MH, Elamin KB, Abu Elnour NO, Elamin MB, Alkatib AA, Fatourechi MM et al (2011) Clinical review: the effect of vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011(96):2997–3006
89. Morley JE (2011) Should frailty be treated with testosterone? Aging Male 14:1–3
90. Morley JE, Fe Kaiser, Perry HM 3rd, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ (1997) Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46:410–413
91. Baumgartner RN, Dl Waters, Gallagher D, Morley JE, Garry PJ (1999) Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 107:123–136
92. Morley JE, Perry HM 3rd, Kaiser FE, Kraenzle D, Jensen J, Houston K, Mattammal M, Perry HM Jr (1993) Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 41:149–152
93. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ et al (2005) Exogenous testosterone (T) alone or with finasteride increses physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502–1510
94. Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C (1997) Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial. J Clin Endocrinol Metab 82:1661–1667
95. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE (2003) Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A 58:618–625
96. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE et al (2005) Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrniol Metab 90:678–688
97. Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA et al (2010) Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 95:639–650
98. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO et al (2010) Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 58:1134–1143
99. Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR et al (2011) Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 66:1090–1099
100. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M et al (2009) Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 54:919–927
101. Iellamo F, Volterrano M, Caminiti G, Karam R, Massaro R, Fini M et al (2010) Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 56:1310–1316
102. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS (2006) Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 27:57–64
103. Stout M, Tew GA, Doll H, Zwierska I, Woodroofe N, Channer KS, Saxton JM (2012) Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. Am Heart J 164:893–901
104. Morley JE, Perry HM 3rd (2003) Androgens and women at the menopause and beyond. J Gerontol A Biol Sci Med Sci 58:M409–M416
105. Chapman IM, Visvanathan R, Hammond AJ, Morley JE, Field JB, Tai K et al (2009) Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr 89:880–889
106. Wolfe R, Ferrando A, Sheffield-Moore M, Urban R (2000) Testosterone and muscle protein metabolism. Mayo Clin Proc 75(Suppl):S55–S59
107. Ferrando AA, Sheffield-Moore M, Paddon-Jones D, Wolfe RR, Urban RJ (2003) Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab 88:358–362
108. Kovacheva EL, Hikim AP, Shen R, Sinha I, Sinha-Hikim I (2010) Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrniology 151:628–638
109. Harin MT, Siddiqui AM, Armbrecht HJ, Kevorkian RT, Kim MJ, Haas MJ, Mazza A, Kumar VB, Green M, Banks WA, Morley JE (2011) Testosterone modulates gene expression pathways regulating nutrient accumulation, glucose metabolism and protein turnover in mouse skeletal muscle. Int J Androl 34:55–68
110. Morley JE (2013) Scientific overview of hormone treatment used for rejuvenation. Fertil Steril 99:1807–1813
111. Carona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, Maggi M (2014) Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 13:1327–1351
112. Mogentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM (2015) Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc 90:224–251
113. Borst SE, Shuster JJ, Zou B, Ye F, Jia H, Wokhlu A, Yarrow JF (2014) Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Med 12:211–215
114. Morley JE, Malmstrom TK, Rodriguez-Manas L, Sinclair AJ (2014) Frailty, sarcopenia and disabetes. J Am Med Dir Assoc 15:853–859
115. Landi F, Onder G, Bernabei R (2013) Sarcopenia and diabetes: two sides of the same coin. J Am Med Dir Assoc 14:540–541
116. Leenders M, Verdijk LB, van der Hoeven L, Adam JJ, van Kranenburg J, Nilwik R, van Loon LJ (2013) Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc 14:585–592
117. Muraleedharan V, March H, Kapoor D, Channer KS, Jones TH (2013) Tesosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 169:725–733
118. Nieschlag E (2015) Current topics in testosterone replacement of hypogonadal men. Best Pract Res Clin Endocrinol Metab 29:77–90
119. Irwig MS (2014) Bone health in hypogonadal men. Curr Opin Urol 24:608–613
120. Sharma S, Arneja A, McLean L, Duerksen D, Leslie W, Sciberras D, Lertzman M (2008) Anabolic steroids in COPD: a review and preliminary results of a randomized trial. Chron Respir Dis 5:169–176
121. Frisoli A Jr, Chaves PH, Pinheiro MM, Vl Szejnfeld (2005) The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis: a double-blind, randomized, placebo-controlled clinical trial. J Gerontol A 60:648–653
122. Macdonald JH, Marcora SM, Jibani MM, Kumwenda MJ, Ahmed W, Lemmey AB (2007) Nandrolone decanoate as anabolic therapy in chronic kidney disease: a randomized phase II dose-finding study. Nephron Clin Pract 106:c125–c135
123. Farooqi V, van den Berg ME, Cameron ID, Crotty M (2014) Anabolic steroids for rehabilitation after hip fracture in older people. Cochrane Database Syst Rev 10:CD008887
124. Papanicolaou DA, Ather SN, Zhu H, Zhou Y, Lutkiewicz J, Scott BB, Chandler J (2013) A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. J Nutr Health Aging 17:533–543
125. Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y et al (2009) Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem 52:3598–3617
126. Bhasin S, Jasuja R (2009) Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 12:232–240
127. Basario S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R et al (2013) The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A 68:87–95
128. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST et al (2011) The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2:153–161
129. Dobs AS, Boccia RV, Croot CC, Gabrial NY, Dalton JT, Hancock ML et al (2013) Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomized controlled phase 2 trial. Lancet Oncol 14:335–345
130. Steiner MS (2013) Enobosarm, a selective androgen receptor modulator, increases lean body mass in advanced non-small cell lung cancer patients in two pivotal, international phase 3 trials. J Cachexia Sarcopenia Muscle 4:69. doi:10.1007/s13539-013-0123-9
131. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF et al (1990) Effects of human growth hormone in men over 60 years old. N Engl J Med 323:1–6
132. Cohn L, Feller AG, Draper MW, Rudman IW, Rudman D (1993) Carpal tunnel syndrome and gynaecomastia druing growth hormone treatment of elderly men with low circulating IGF-1 concentrations. Clin Endocrniol (Oxf) 39:417–425
133. Kim MJ, Morley JE (2005) The hormonal fountains of youth: myth or reality? J Endocrinol Invest 28(11):5–14
134. Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE et al (2002) Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288:2282–2292
135. Kaiser FE, Silver AJ, Morley JE (1991) The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc 39:235–240
136. Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Am Garber, Hoffman AR (2007) Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 146:104–115
137. Giannoulis MG, Martin FC, Nair KS, Umpleby AM, Sonksen P (2012) Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev 33:314–377
138. Sullivan DH, Carter WJ, Warr WR, Williams LH (1998) Side effects resulting from the use of growth hormone and insulin-like growth factor-1 as combined therapy to frail elderly patients. J Gerontol A 53:M183–M187
139. Gaskin FS, Farr SA, Banks WA, Kumar VB, Morley JE (2008) Ghrelin-induced feeding is dependent on nitric oxide. Peptides 24:913–918
140. Argiles JM, Stemmler B (2013) The potential of ghrelin in the treatment of cancer cachexia. Expert Opin Biol Ther 13:67–76
141. Miyazaki T, Tanaka N, Hirai H, Yokobori T, Sano A, Sakai M et al (2012) Ghrelin level and body weight loss after esophagectomy for esophageal cancer. J Surg Res 176:74–78
142. Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J (2015) Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomized, placebo-controlled, double-blind trials. Lancet Oncol 16:108–116
143. Temel J, Bondarde S, Jain M, Yun Y, Duus E, Allen S et al (2013) Efficacy and safety results from a phase II study of anamorelin HC21, a ghrelin receptor agonist, in NSCLC patients. J Cachexia Sarcopenia Muscle 4:334
144. White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K et al (2009) Effects of an oral growth hormone scretagogue in older adults. J Clin Endocrinol Metab 94:1198–1206
145. Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y et al (2011) MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fractures: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr 53:183–189
146. Elkina Y, vono Haehling S, Anker SD, Springer J (2011) The role of muyostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle 2:143–151
147. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350:2682–2688
148. Saremi A, Gharakhanloo R, Sharghi S, Gharaati MR, Larijani B, Omidfar K (2010) Effects of oral cretine and resistance training on serum myostatin and GASP-1. Mol Cell Endocrniol 317:25–30
149. Walter MC, Reilich P, Lochmuller H, Kohnen R, Schlotter B, Hautmann H, Dunkl E et al (2002) Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study. J Neurol 249:1717–1722
150. Tsuchida K (2008) Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel 11:487–494
151. Wagner KR, Fleckenstein JL, Amato AA, Barhn RJ, Bushby K, Eagle M, Florence JM, King WM et al (2008) A phase I/II Trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63:561–571
152. Padhi D, Higano CS, Shore ND, Sieber P, Rasmussen E, Smith MR (2014) Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 99:E1967–E1975
153. Fajardo RJ, Manoharan RK, Pearsall RS, Davies MV, Marvell T, Monnell TE et al (2010) Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 46:64–71
154. Attie KM, Brogstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE et al (2013) A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve 47:416–423
155. Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, Lach-Trifilieff E, Trendelenburg AU, Laurent D, Glass DJ, Roubenoff R, Tseng BS, Greenberg SA (2014) Treatment of Sporadic inclusion body myositis with bimagrumab. Neurology 83:2239–2246
156. Potsch MS, Tschirner A, Palus S, von Haehling S, Doehner W, Beadle J, Coats AJ, Anker SD, Springer J (2014) The anabolic catabolic transforming agenda (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle 5:149–158
157. Steward Coats AJ, Srinivasan Surendran J, Chicarmana H, Vangipuram SR, Bhatt NN, Jain M et al (2011) The ACT-ONE trial, a multicenter, randomized, double-blind, placebo-controlled dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle 2:201–207
158. Hutcheon SD, Gillespie ND, Crombie IK, Struthers AD, McMurdo ME (2002) Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomized double blind placebo controlled trial. Heart 88:373–377
159. Sumukadas D, Witham MD, Struthers AD, McMurdo ME (2007) Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ 177:867–874
160. Sumukadas D, Band M, Miller S, Cvoro V, Witham M, Struthers A, McConnachie A, Lloud SM, McMurdo M (2014) Do ACE inhibitors improve the response to exercise training in functionally impaired older adults? A randomized controlled trial. J Gerontol A 69:736–743
161. Peters R, Beckett N, Burch L, de Vernejoul MC, Liu L, Duggan J et al (2010) The effect of treatment based on diuretic (indapamide) ± ACE inhibitor (perindopril) on fractures in the hypertension in the very elderly trial (HYVET). Age Ageing 39:609–616
162. Malik F (2013) Fast skeletal muscle troponin activators and their application to disease-preclinical characterization. In: Abstracts, 7th Cachexia Conference, Kobe. p 50